The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Fosamax     sodium[4-amino-1-hydroxy-1- (hydroxy-oxido...

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of MK 217


High impact information on MK 217


Chemical compound and disease context of MK 217


Biological context of MK 217


Anatomical context of MK 217

  • Exposure of the esophageal mucosa for a prolonged period to alendronate sodium tablet can also cause mild esophageal irritation [20].
  • The purpose of this overview is to provide a summary of recent data on the clinical safety and efficacy of alendronate sodium, an amino-bisphosphonate that is a potent and specific inhibitor of osteoclast mediated bone resorption, in the treatment of osteoporosis in postmenopausal women [21].
  • The purpose of this study was to evaluate the potential of alendronate sodium (ALN), a biphosohonate to stimulate hard tissue formation in pulpotomized (amputated) rat molars [22].

Associations of MK 217 with other chemical compounds


Gene context of MK 217


Analytical, diagnostic and therapeutic context of MK 217


  1. Dose-response study of alendronate sodium for the treatment of cancer-associated hypercalcemia. Nussbaum, S.R., Warrell, R.P., Rude, R., Glusman, J., Bilezikian, J.P., Stewart, A.F., Stepanavage, M., Sacco, J.F., Averbuch, S.D., Gertz, B.J. J. Clin. Oncol. (1993) [Pubmed]
  2. Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis. Tucci, J.R., Tonino, R.P., Emkey, R.D., Peverly, C.A., Kher, U., Santora, A.C. Am. J. Med. (1996) [Pubmed]
  3. Alendronate and naproxen are synergistic for development of gastric ulcers. Graham, D.Y., Malaty, H.M. Arch. Intern. Med. (2001) [Pubmed]
  4. Alendronate-induced esophagitis: case report of a recently recognized form of severe esophagitis with esophageal stricture--radiographic features. Ryan, J.M., Kelsey, P., Ryan, B.M., Mueller, P.R. Radiology. (1998) [Pubmed]
  5. Alendronate gastric ulcers. Graham, D.Y., Malaty, H.M. Aliment. Pharmacol. Ther. (1999) [Pubmed]
  6. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. McClung, M.R., San Martin, J., Miller, P.D., Civitelli, R., Bandeira, F., Omizo, M., Donley, D.W., Dalsky, G.P., Eriksen, E.F. Arch. Intern. Med. (2005) [Pubmed]
  7. Gastric and duodenal safety of daily alendronate. Donahue, J.G., Chan, K.A., Andrade, S.E., Beck, A., Boles, M., Buist, D.S., Carey, V.J., Chandler, J.M., Chase, G.A., Ettinger, B., Fishman, P., Goodman, M., Guess, H.A., Gurwitz, J.H., LaCroix, A.Z., Levin, T.R., Platt, R. Arch. Intern. Med. (2002) [Pubmed]
  8. Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Chesnut, C.H., McClung, M.R., Ensrud, K.E., Bell, N.H., Genant, H.K., Harris, S.T., Singer, F.R., Stock, J.L., Yood, R.A., Delmas, P.D. Am. J. Med. (1995) [Pubmed]
  9. The bisphosphonate alendronate (MK-217) inhibits bone loss due to ovariectomy in rats. Seedor, J.G., Quartuccio, H.A., Thompson, D.D. J. Bone Miner. Res. (1991) [Pubmed]
  10. Clinical pharmacology of alendronate sodium. Gertz, B.J., Holland, S.D., Kline, W.F., Matuszewski, B.K., Porras, A.G. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. (1993) [Pubmed]
  11. Bisphosphonates for controlling pain from metastatic bone disease. Diener, K.M. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. (1996) [Pubmed]
  12. Novel bone-targeted Src tyrosine kinase inhibitor drug discovery. Shakespeare, W.C., Metcalf, C.A., Wang, Y., Sundaramoorthi, R., Keenan, T., Weigele, M., Bohacek, R.S., Dalgarno, D.C., Sawyer, T.K. Current opinion in drug discovery & development. (2003) [Pubmed]
  13. I am 51 years old, perimenopausal, have irritable bowel syndrome and a family history of breast cancer, and am told my bones are thinning. These conditions would seem to rule out my use of estrogen or Fosamax. I weight train and take 1,500 mg of calcium a day to stave off osteoporosis. What's left? Robb-Nicholson, C. Harvard women's health watch. (1998) [Pubmed]
  14. Effects of trans-resveratrol from Polygonum cuspidatum on bone loss using the ovariectomized rat model. Liu, Z.P., Li, W.X., Yu, B., Huang, J., Sun, J., Huo, J.S., Liu, C.X. Journal of medicinal food. (2005) [Pubmed]
  15. Aromatase inhibitors and bone loss. Perez, E.A., Weilbaecher, K. Oncology (Williston Park, N.Y.) (2006) [Pubmed]
  16. High-performance liquid chromatography method for determining alendronate sodium in human plasma by detecting fluorescence: application to a pharmacokinetic study in humans. Yun, M.H., Kwon, K.I. Journal of pharmaceutical and biomedical analysis. (2006) [Pubmed]
  17. Disintegration/dissolution profiles of copies of Fosamax (alendronate). Epstein, S., Cryer, B., Ragi, S., Zanchetta, J.R., Walliser, J., Chow, J., Johnson, M.A., Leyes, A.E. Current medical research and opinion. (2003) [Pubmed]
  18. Qualitative analysis of peripheral peri-implant bone and influence of alendronate sodium on early bone regeneration. Meraw, S.J., Reeve, C.M. J. Periodontol. (1999) [Pubmed]
  19. Case in point. Counseling about hormone replacement therapy. Mahon, S.M. Oncology nursing forum. (1998) [Pubmed]
  20. Esophageal irritation due to alendronate sodium tablets: possible mechanisms. Peter, C.P., Handt, L.K., Smith, S.M. Dig. Dis. Sci. (1998) [Pubmed]
  21. An overview of the results of clinical trials with alendronate, a promising treatment of osteoporosis in postmenopausal women. Hirsch, L.J., Pryor-Tillotson, S. Ann. Ital. Med. Int. (1995) [Pubmed]
  22. Histological comparison of alendronate, calcium hydroxide and formocresol in amputated rat molar. Cengiz, S.B., Batirbaygil, Y., Onur, M.A., Atilla, P., Asan, E., Altay, N., Cehreli, Z.C. Dental traumatology : official publication of International Association for Dental Traumatology. (2005) [Pubmed]
  23. Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. Bonnick, S., Saag, K.G., Kiel, D.P., McClung, M., Hochberg, M., Burnett, S.A., Sebba, A., Kagan, R., Chen, E., Thompson, D.E., de Papp, A.E. J. Clin. Endocrinol. Metab. (2006) [Pubmed]
  24. A review of clinical trials of therapies for osteoporosis using fracture as an end point. Blank, R.D., Bockman, R.S. Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry. (1999) [Pubmed]
  25. Formulation and in vitro evaluation of bisphosphonate loaded microspheres for implantation in osteolysis. Samdancioglu, S., Calis, S., Sumnu, M., Atilla Hincal, A. Drug development and industrial pharmacy. (2006) [Pubmed]
  26. Postoperative hypocalcemic tetany caused by fleet phospho-soda preparation in a patient taking alendronate sodium: report of a case. Campisi, P., Badhwar, V., Morin, S., Trudel, J.L. Dis. Colon Rectum (1999) [Pubmed]
  27. Application of a semi-automated 96-well format solid-phase extraction, column-switching, fluorescence detection protocol for the determination of alendronate in human urine samples obtained from a bioequivalence study. Apostolou, C., Dotsikas, Y., Kousoulos, C., Tsatsou, G., Colocouri, F., Soumelas, G.S., Loukas, Y.L. Journal of pharmaceutical and biomedical analysis (2007) [Pubmed]
  28. Effects of alendronate on bone turnover markers in early postmenopausal women. Yang, T.S., Tsan, S.H., Chen, C.R., Chang, S.P., Yuan, C.C. Zhonghua Yi Xue Za Zhi (Taipei) (1998) [Pubmed]
  29. The effect of alendronate sodium on alveolar bone loss in periodontitis (clinical trial). El-Shinnawi, U.M., El-Tantawy, S.I. Journal of the International Academy of Periodontology. (2003) [Pubmed]
  30. Synthesis and study of alendronate derivatives as potential prodrugs of alendronate sodium for the treatment of low bone density and osteoporosis. Vachal, P., Hale, J.J., Lu, Z., Streckfuss, E.C., Mills, S.G., MacCoss, M., Yin, D.H., Algayer, K., Manser, K., Kesisoglou, F., Ghosh, S., Alani, L.L. J. Med. Chem. (2006) [Pubmed]
  31. Treatment of postmenopausal osteoporosis with continuous daily oral alendronate in comparison with either placebo or intranasal salmon calcitonin. Adami, S., Baroni, M.C., Broggini, M., Carratelli, L., Caruso, I., Gnessi, L., Laurenzi, M., Lombardi, A., Norbiato, G., Ortolani, S. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. (1993) [Pubmed]
  32. The John Charnley Award. Inhibition of wear debris mediated osteolysis in a canine total hip arthroplasty model. Shanbhag, A.S., Hasselman, C.T., Rubash, H.E. Clin. Orthop. Relat. Res. (1997) [Pubmed]
  33. Progression of coronary artery calcification in patients taking alendronate for osteoporosis. Hill, J.A., Goldin, J.G., Gjertson, D., Emerick, A.M., Greaser, L.D., Yoon, H.C., Khorrami, S., Aziz, D., Adams, J.S. Academic radiology. (2002) [Pubmed]
WikiGenes - Universities